HRMY

Harmony Biosciences Holdings Inc

Jan 28 • 04:00PM ET

36.84

-0.84 -2.23 %

Healthcare • Biotechnology • USA • NASD

Peers: MRK LLY PFE JNJ AMGN VRTX REGN GILD BIIB NBIX

| Held by: CALF JSMD USVM SFLO JSML FYX ECML RNIN SIXS VFMF

Index	RUT	P/E	11.60	EPS (ttm)	3.18	Insider Own	15.02%	Shs Outstand	57.60M	Perf Week	0.41%
Market Cap	2.12B	Forward P/E	9.11	EPS next Y	4.05	Insider Trans	-1.05%	Shs Float	48.95M	Perf Month	-3.38%
Enterprise Value	1.68B	PEG	0.39	EPS next Q	0.87	Inst Own	85.33%	Short Float	12.24%	Perf Quarter	22.35%
Income	185.68M	P/S	2.57	EPS this Y	26.37%	Inst Trans	-4.80%	Short Ratio	7.87	Perf Half Y	3.92%
Sales	825.94M	P/B	2.54	EPS next Y	27.55%	ROA	17.38%	Short Interest	5.99M	Perf YTD	-1.55%
Book/sh	14.50	P/C	3.15	EPS next 5Y	23.31%	ROE	25.93%	52W High	40.87 -9.86%	Perf Year	-3.69%
Cash/sh	11.68	P/FCF	7.15	EPS past 3/5Y	62.64% -	ROIC	18.87%	52W Low	25.52 44.36%	Perf 3Y	-24.92%
Dividend Est.	-	EV/EBITDA	6.72	Sales past 3/5Y	32.76% 160.18%	Gross Margin	74.81%	Volatility	2.70% 3.45%	Perf 5Y	1.77%
Dividend TTM	-	EV/Sales	2.03	EPS Y/Y TTM	50.86%	Oper. Margin	27.32%	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.72	Sales Y/Y TTM	21.13%	Profit Margin	22.48%	RSI (14)	48.81	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	3.75	EPS Q/Q	9.20%	SMA20	-0.52%	Beta	0.84	Target Price	46.45
Payout	0.00%	Debt/Eq	0.27	Sales Q/Q	28.71%	SMA50	-0.57%	Rel Volume	0.66	Prev Close	37.68
Employees	268	LT Debt/Eq	0.18	Earnings	Nov 04 BMO	SMA200	9.49%	Avg Volume	760.78K	Price	36.84
IPO	Aug 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.26% 5.55%	Trades		Volume	503,087	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-25	Initiated	Truist	Buy	$48
Jul-10-25	Resumed	Goldman	Neutral	$33
Jun-02-25	Resumed	Oppenheimer	Outperform	$61
Feb-11-25	Initiated	Deutsche Bank	Buy	$55
Dec-17-24	Initiated	H.C. Wainwright	Buy	$75
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy	$56
Jun-21-24	Initiated	Citigroup	Buy	$48
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform	$30
Sep-25-23	Downgrade	Goldman	Neutral → Sell	$40 → $31
Sep-07-23	Initiated	Berenberg	Buy	$59
Apr-20-23	Initiated	BofA Securities	Neutral	$35
Oct-14-22	Upgrade	Jefferies	Hold → Buy	$57 → $61
Oct-14-22	Upgrade	Janney	Neutral → Buy	$57 → $61
Aug-03-22	Downgrade	Jefferies	Buy → Hold	$57
Jul-13-22	Downgrade	Goldman	Buy → Neutral	$55
Jul-07-22	Initiated	Mizuho	Buy	$64
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight	$63
Dec-01-21	Initiated	Oppenheimer	Outperform	$55
Nov-04-21	Initiated	Raymond James	Outperform	$58

Show Previous Ratings

Today 12:24PM	How Harmony Biosciences Can Prove Its Skeptics Wrong (Motley Fool)
12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 12:21PM	I Was Shocked to Find This Value-Priced Biotech Growth Stock (Motley Fool)
11:40AM	HRMY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Loading…
09:40AM	Should Value Investors Buy Harmony Biosciences (HRMY) Stock? (Zacks)
Jan-15-26 08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-13-26 12:45PM	Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why (Zacks) -6.56%
Jan-12-26 08:05AM	Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation (Business Wire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? (Zacks)
Jan-07-26 08:05AM	Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-08-25 08:05AM	Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome (Business Wire)
Dec-02-25 08:05AM	Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-24-25 08:05AM	Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation (Business Wire)
08:05AM	Loading…
Nov-19-25 08:05AM	Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence (Business Wire)
Nov-18-25 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 08:01AM	Harmony Biosciences Holdings Inc (HRMY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M (Business Wire)
Nov-03-25 07:38AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q3 2025 Result (GuruFocus.com)
Oct-31-25 10:29PM	Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY) (Insider Monkey)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-23-25 08:05AM	Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance (Business Wire) +12.68%
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Sep-29-25 06:54PM	H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback (Insider Monkey)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)
Sep-24-25 01:20PM	Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study (Benzinga) -16.56%
01:02PM	Loading…
01:02PM	Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble (Investor's Business Daily)
08:00AM	Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome (Business Wire)
Sep-17-25 02:27PM	UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT (Insider Monkey)
Sep-15-25 02:18PM	11 fast-growing small-cap stocks that could get a boost from the Fed's next move (MarketWatch)
Aug-29-25 05:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Expands WAKIX With FDA Nod for Prader-Willi (Insider Monkey)
Aug-26-25 08:05AM	Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress (Business Wire)
Aug-21-25 08:05AM	Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference (Business Wire)
Aug-12-25 09:11AM	H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) (Insider Monkey)
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks)
Aug-05-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 (Business Wire)
Aug-04-25 04:35PM	Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory (Insider Monkey)
09:36AM	Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-29-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-25-25 09:58AM	REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth? (Zacks)
Jul-23-25 11:04AM	Harmony Biosciences Advances Pipeline While Navigating Analyst Caution (Insider Monkey)
Jul-22-25 01:30PM	Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View (Zacks)
08:53AM	5 High Earnings Yield Stocks to Tap Into Value Investing Gains (Zacks)
08:05AM	Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
Jul-17-25 12:10PM	Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-15-25 12:45PM	3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY) (Zacks)
11:40AM	HRMY vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
09:55AM	Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? (Zacks)
08:05AM	Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series (Business Wire)
Jul-14-25 11:30AM	Mizuho Reaffirms "Outperform" on Harmony Biosciences (HRMY) for BP1.15205 Data (Insider Monkey)
Jul-10-25 11:41AM	Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise (Insider Monkey)
11:13AM	H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY) (Insider Monkey)
Jul-04-25 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
Jun-24-25 05:33PM	Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY) (Insider Monkey)
Jun-11-25 08:05AM	Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 (Business Wire)
Jun-09-25 12:08PM	Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory (Insider Monkey)
Jun-06-25 09:25AM	Harmony Biosciences settles generic drug litigation, strengthens patent (TipRanks)
Jun-05-25 08:05AM	Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation (Business Wire)
Jun-04-25 08:05AM	Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-07-25 03:09AM	Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
02:05AM	Q1 2025 Harmony Biosciences Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 08:50AM	Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates (Zacks) +6.98%
07:30AM	Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance (Business Wire)
May-05-25 09:45AM	Harmony Biosciences Holdings Inc (HRMY) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-01-25 12:10PM	Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again (Zacks)
10:01AM	Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-29-25 08:05AM	Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 (Business Wire)
Apr-21-25 07:36AM	JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-08-25 08:05AM	Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome (Business Wire)
Apr-04-25 09:17AM	Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory (Insider Monkey) -5.52%
Apr-03-25 08:05AM	Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors (Business Wire)
Mar-26-25 11:23PM	Is Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
08:05AM	Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-24-25 12:09PM	Harmony Biosciences: A Compelling Risk-Reward Opportunity (SeekingAlpha)
08:05AM	Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands (Business Wire)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-07-25 03:36AM	Harmony Biosciences Holdings, Inc. (HRMY): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts (Insider Monkey)
Mar-04-25 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Feb-26-25 09:40AM	Should Value Investors Buy Harmony Biosciences (HRMY) Stock? (Zacks) -9.47%
03:39AM	Q4 2024 Harmony Biosciences Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Harmony Biosciences Holdings Inc (HRMY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-25-25 02:15PM	Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript (Motley Fool) +8.16%
12:31PM	Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
08:50AM	Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs (Business Wire)
01:30AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q4 2024 Result (GuruFocus.com)
Feb-24-25 01:04PM	Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now? (Insider Monkey)
12:00PM	Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why (Zacks)
Feb-19-25 04:39PM	Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug (Investor's Business Daily) -9.64%
02:24PM	Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder (Benzinga)
08:05AM	Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia (Business Wire)
Feb-18-25 08:05AM	Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (Business Wire)

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 25 '26	Option Exercise	0.00	4,725	0	4,725	Jan 26 04:49 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 24 '26	Option Exercise	0.00	3,813	0	3,813	Jan 26 04:49 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 25 '26	Option Exercise	0.00	2,600	0	2,600	Jan 26 04:48 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 24 '26	Option Exercise	0.00	2,500	0	2,500	Jan 26 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 25 '26	Option Exercise	0.00	2,662	0	2,662	Jan 26 04:45 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 24 '26	Option Exercise	0.00	2,188	0	2,188	Jan 26 04:45 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 25 '26	Option Exercise	0.00	13,000	0	13,000	Jan 26 04:43 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 24 '26	Option Exercise	0.00	10,500	0	10,500	Jan 26 04:43 PM
SANDIP KAPADIA	Officer	Jan 26 '26	Proposed Sale	36.82	3,746	137,928		Jan 26 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 15 '26	Sale	35.92	20,961	752,833	0	Jan 20 08:39 PM
SANDIP KAPADIA	Officer	Jan 15 '26	Proposed Sale	36.04	20,961	755,434		Jan 15 04:22 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Option Exercise	8.22	20,000	164,400	20,000	Dec 17 05:25 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Sale	40.11	25,933	1,040,103	0	Dec 17 05:25 PM
JEFFREY M DAYNO	Director	Dec 12 '25	Proposed Sale	39.59	25,933	1,026,687		Dec 12 04:25 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Option Exercise	29.03	20,000	580,600	20,000	Dec 09 04:10 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Sale	39.54	20,000	790,896	0	Dec 09 04:10 PM
SANDIP KAPADIA	Officer	Dec 05 '25	Proposed Sale	38.25	20,000	765,000		Dec 05 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Nov 21 '25	Sale	35.00	3,427	119,945	0	Nov 25 04:10 PM
SANDIP KAPADIA	Officer	Nov 21 '25	Proposed Sale	33.39	3,427	114,428		Nov 21 04:46 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Sep 30 '25	Option Exercise	0.00	45,000	0	45,000	Oct 02 04:05 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Aug 15 '25	Sale	36.50	21,573	787,378	0	Aug 19 04:15 PM
SANDIP KAPADIA	Officer	Aug 15 '25	Proposed Sale	36.51	21,573	787,630		Aug 15 04:28 PM
JEFFREY G DIERKS	Former Officer	Jun 10 '25	Proposed Sale	35.98	5,615	202,009		Jun 10 04:29 PM
JEFFREY G DIERKS	Former Officer	May 19 '25	Proposed Sale	35.56	9,844	350,083		May 19 04:06 PM
JEFFREY G DIERKS	Former Officer	May 16 '25	Proposed Sale	35.09	2,292	80,427		May 16 04:21 PM
JEFFREY G DIERKS	Former Officer	May 12 '25	Proposed Sale	35.19	5,000	175,955		May 12 04:18 PM
Budur Kumar	CHIEF MEDICAL OFFICER	May 01 '25	Option Exercise	0.00	18,750	0	18,750	May 09 04:07 PM
JEFFREY G DIERKS	Former Officer	May 09 '25	Proposed Sale	34.22	4,972	170,119		May 09 04:07 PM
JEFFREY G DIERKS	Former Officer	May 08 '25	Proposed Sale	33.76	13,000	438,873		May 08 04:15 PM
JEFFREY G DIERKS	Former Officer	May 07 '25	Proposed Sale	32.47	31,000	1,006,645		May 07 04:13 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Apr 01 '25	Sale	32.54	6,987	227,386	0	Apr 03 04:15 PM
SANDIP KAPADIA	Officer	Apr 01 '25	Proposed Sale	33.19	6,986	231,865		Apr 01 04:27 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Mar 29 '25	Option Exercise	0.00	15,000	0	15,000	Apr 01 04:10 PM
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 03 '25	Option Exercise	8.22	4,869	40,023	4,869	Mar 05 04:05 PM
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 03 '25	Sale	32.67	4,869	159,090	0	Mar 05 04:05 PM
JEFFREY G DIERKS	Officer	Mar 03 '25	Proposed Sale	33.85	4,869	164,816		Mar 03 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HRMY

Harmony Biosciences Holdings Inc

Upgrade your FINVIZ experience